Nebulized ipratropium bromide in the treatment of acute asthma.
The aim of this study was to investigate the effects of nebulized ipratropium in patients with acute asthma in order to determine whether it augments the bronchodilator effect of a beta agonist drug. A total of 28 patients with acute asthma were randomly allocated to treatment every six hours with either 1 mg nebulized fenoterol (group A) or 1 mg fenoterol and 0.5 mg ipratropium (group B). There was no significant difference between the mean FEV1 of the two groups prior to treatment and increasing the dose of fenoterol from 1 mg to 2 mg did not increase the response. However the mean change in FEV1 after 48 hours (expressed as a percentage of the predicted maximal response) was 40.1 +/- 7.2 percent in group A and 54.3 +/- 9.2 percent in group B (p less than 0.005). It was concluded that the response of patients with acute asthma to fenoterol was significantly enhanced by the addition of the anticholinergic agent ipratropium bromide.
Bryant
D H
DH
D000208:Acute Disease; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001286:Atropine Derivatives / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D004338:Drug Combinations; D004357:Drug Synergism; D005260:Female; D005280:Fenoterol / Q000627:therapeutic use; D005541:Forced Expiratory Volume; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012138:Respiratory Therapy
D000318:Adrenergic beta-Agonists; D001286:Atropine Derivatives; D001993:Bronchodilator Agents; D004338:Drug Combinations; D005280:Fenoterol; D009241:Ipratropium